Novavax (NVAX) Cost of Revenue (2011 - 2026)

Novavax's Cost of Revenue history runs 10 years deep, the most recent figure standing at $30.7 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 117.46% year-over-year to $30.7 million; the TTM figure through Mar 2026 stood at $89.6 million (down 43.15% YoY), while the FY2025 annual figure was $73.0 million, down 63.97% from the prior year.
• Cost of Revenue was $30.7 million for Q1 2026 at Novavax, up from $22.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $434.6 million in Q3 2022 to a low of $14.1 million in Q1 2025.
• Historically, Cost of Revenue has averaged $91.3 million across 5 years, with a median of $46.2 million in 2024.
• Biggest YoY gain for Cost of Revenue was 124.19% in 2023; the steepest drop was 79.42% in 2023.
• A 5-year view of Cost of Revenue shows it stood at $181.8 million in 2022, then dropped by 14.74% to $155.0 million in 2023, then sank by 76.34% to $36.7 million in 2024, then tumbled by 39.72% to $22.1 million in 2025, then soared by 38.87% to $30.7 million in 2026.
• The last three Cost of Revenue figures came in at $30.7 million (Q1 2026), $22.1 million (Q4 2025), and $21.5 million (Q3 2025), per Business Quant data.